全文获取类型
收费全文 | 17313篇 |
免费 | 2480篇 |
国内免费 | 331篇 |
专业分类
耳鼻咽喉 | 260篇 |
儿科学 | 488篇 |
妇产科学 | 328篇 |
基础医学 | 1010篇 |
口腔科学 | 736篇 |
临床医学 | 832篇 |
内科学 | 2700篇 |
皮肤病学 | 173篇 |
神经病学 | 654篇 |
特种医学 | 358篇 |
外国民族医学 | 18篇 |
外科学 | 4109篇 |
综合类 | 1086篇 |
预防医学 | 950篇 |
眼科学 | 116篇 |
药学 | 488篇 |
3篇 | |
中国医学 | 194篇 |
肿瘤学 | 5621篇 |
出版年
2023年 | 531篇 |
2022年 | 501篇 |
2021年 | 985篇 |
2020年 | 1141篇 |
2019年 | 1096篇 |
2018年 | 1031篇 |
2017年 | 966篇 |
2016年 | 868篇 |
2015年 | 963篇 |
2014年 | 1304篇 |
2013年 | 1298篇 |
2012年 | 888篇 |
2011年 | 897篇 |
2010年 | 659篇 |
2009年 | 732篇 |
2008年 | 824篇 |
2007年 | 701篇 |
2006年 | 587篇 |
2005年 | 543篇 |
2004年 | 504篇 |
2003年 | 446篇 |
2002年 | 367篇 |
2001年 | 287篇 |
2000年 | 262篇 |
1999年 | 223篇 |
1998年 | 173篇 |
1997年 | 159篇 |
1996年 | 123篇 |
1995年 | 111篇 |
1994年 | 112篇 |
1993年 | 86篇 |
1992年 | 87篇 |
1991年 | 82篇 |
1990年 | 70篇 |
1989年 | 55篇 |
1988年 | 67篇 |
1987年 | 51篇 |
1986年 | 49篇 |
1985年 | 49篇 |
1984年 | 46篇 |
1983年 | 34篇 |
1982年 | 30篇 |
1981年 | 28篇 |
1980年 | 28篇 |
1979年 | 23篇 |
1978年 | 18篇 |
1977年 | 12篇 |
1976年 | 9篇 |
1975年 | 7篇 |
1966年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的:回顾性分析比较心肌梗死(MI)后不同病程心力衰竭(心衰)患者应用沙库巴曲缬沙坦(Sacubitril/Valsartan,LCZ696)的
临床疗效是否存在差异。方法: 收集2018 年1 月1 日—2020 年6 月30 日在天津市第一中心医院心内科住院并首次服用
LCZ696 的MI 后心衰患者共150 例,分为并发心衰组,心衰病程≤2 年组和心衰病程>2 年组,各50 例,以治疗后3、6、12 个月
为时间节点进行为期1 年的回访,观察心脏超声指标变化和生存情况,并用Cox 回归分析影响疗效的因素。结果:3组患者左心
室射血分数(LVEF)(F=62.111,P<0.01)和舒张末期内径(LVEDD)(F=38.444,P<0.01)分别呈逐渐上升和下降趋势,其中在并发
心衰组的变化最显著,组间差异存在统计学意义。3 组间累积无终点事件生存率(90.0%、57.8%、35.3%)有统计学意义(字2=
32.754,P<0.01)。Cox 回归分析发现长心衰病程患者终点事件发生的风险大(HR=10.407,95%CI:3.957~27.371,P<0.001)。结论:
MI 后心衰患者早期启用LCZ696 更有利于改善左室重构,无事件生存率更高。 相似文献
2.
目的 探讨调强放射治疗对乳腺癌保乳术后患者的影响。方法 选取2015年3月—2019年10月在本院接受保乳术治疗的98例乳腺癌患者作为研究对象,按随机数字表法分为观察组与对照组,每组各49例。对照组采用常规放射治疗,观察组采用调强放射治疗。比较2组疗效、计划靶区剂量学、肌钙蛋白水平、预后情况。结果 观察组疗效总有效率为83.67%,高于对照组的65.31%,差异具有统计学意义(χ2=4.350,P=0.037);观察组计划靶区V100%、V105%分别为(9.68±0.65)%、(1.03±0.06)%,分别低于对照组的(42.02±4.87)%、(24.51±2.54)%,差异具有统计学意义(t=46.076、64.691,P值均<0.001);放疗后,观察组和对照组肌钙蛋白分别为(0.116±0.012)ng/mL、(0.260±0.019)ng/mL,分别高于放疗前的(0.059±0.010)ng/mL、(0.057±0.009)ng/mL,差异具有统计学意义(P<0.05),但观察组肌钙蛋白较对照组低,差异有统计学意义(t=44.855,P<0.001);观察组的无瘤生存率为97.96%,高于对照组的83.67%,差异具有统计学意义(χ2=4.405,P=0.036)。结论 对乳腺癌保乳术后患者辅以调强放射治疗,可提高临床疗效,调节靶区照射剂量均匀性、适应性,避免心肌及其他周围组织损伤,并提高无瘤生存率,改善预后。 相似文献
3.
4.
《Value in health》2022,25(6):1010-1017
ObjectivesSurvival extrapolation for chimeric antigen receptor T-cell therapies is challenging, owing to their unique mechanistic properties that translate to complex hazard functions. Axicabtagene ciloleucel is indicated for the treatment of relapse or refractory diffuse large B-cell lymphoma after 2 or more lines of therapy based on the ZUMA-1 trial. Four data snapshots are available, with minimum follow-up of 12, 24, 36, and 48 months. This analysis explores how survival extrapolations for axicabtagene ciloleucel using ZUMA-1 data can be validated and compared.MethodsThree different parametric modeling approaches were applied: standard parametric, spline-based, and cure-based models. Models were compared using a range of metrics, across the 4 data snapshot, including visual fit, plausibility of long-term estimates, statistical goodness of fit, inspection of hazard plots, point-estimate accuracy, and conditional survival estimates.ResultsStandard and spline-based parametric extrapolations were generally incapable of fitting the ZUMA-1 data well. Cure-based models provided the best fit based on the earliest data snapshot, with extrapolations remaining consistent as data matured. At 48 months, the maximum survival overestimate was 8.3% (Gompertz mixture-cure model) versus the maximum underestimate of 33.5% (Weibull standard parametric model).ConclusionsWhere a plateau in the survival curve is clinically plausible, cure-based models may be helpful in making accurate predictions based on immature data. The ability to reliably extrapolate from maturing data may reduce delays in patient access to potentially lifesaving treatments. Additional research is required to understand how models compare in broader contexts, including different treatments and therapeutic areas. 相似文献
5.
Shareen Forbes Anneliese J. Flatt Denise Bennett Robert Crookston Mirka Pimkova Linda Birtles Andrew Pernet Ruth C. Wood Keith Burling Peter Barker Claire Counter Alistair Lumb Pratik Choudhary Martin K. Rutter Miranda Rosenthal Andrew Sutherland John Casey Paul Johnson James A. M. Shaw 《American journal of transplantation》2022,22(1):154-164
The UK islet allotransplant program is nationally funded to deliver one or two transplants over 12 months to individuals with type 1 diabetes and recurrent severe hypoglycemia. Analyses were undertaken 10 years after program inception to evaluate associations between transplanted mass; single versus two transplants; time between two transplants and graft survival (stimulated C-peptide >50 pmol/L) and function. In total, 84 islet transplant recipients were studied. Uninterrupted graft survival over 12 months was attained in 23 (68%) single and 47 (94%) (p = .002) two transplant recipients (separated by [median (IQR)] 6 (3–8) months). 64% recipients of one or two transplants with uninterrupted function at 12 months sustained graft function at 6 years. Total transplanted mass was associated with Mixed Meal Tolerance Test stimulated C-peptide at 12 months (p < .01). Despite 1.9-fold greater transplanted mass in recipients of two versus one islet infusion (12 218 [9291–15 417] vs. 6442 [5156–7639] IEQ/kg; p < .0001), stimulated C-peptide was not significantly higher. Shorter time between transplants was associated with greater insulin dose reduction at 12 months (beta ?0.35; p = .02). Graft survival over the first 12 months was greater in recipients of two versus one islet transplant in the UK program, although function at 1 and 6 years was comparable. Minimizing the interval between 2 islet infusions may maximize cumulative impact on graft function. 相似文献
6.
Lars Burdorf Christopher T. Laird Donald G. Harris Margaret R. Connolly Zahra Habibabady Emily Redding Natalie A. O'Neill Arielle Cimeno Dawn Parsell Carol Phelps David Ayares Agnes M. Azimzadeh Richard N. Pierson 《American journal of transplantation》2022,22(1):28-45
Galactosyl transferase knock-out pig lungs fail rapidly in baboons. Based on previously identified lung xenograft injury mechanisms, additional expression of human complement and coagulation pathway regulatory proteins, anti-inflammatory enzymes and self-recognition receptors, and knock-down of the β4Gal xenoantigen were tested in various combinations. Transient life-supporting GalTKO.hCD46 lung function was consistently observed in association with either hEPCR (n = 15), hTBM (n = 4), or hEPCR.hTFPI (n = 11), but the loss of vascular barrier function in the xenograft and systemic inflammation in the recipient typically occurred within 24 h. Co-expression of hEPCR and hTBM (n = 11) and additionally blocking multiple pro-inflammatory innate and adaptive immune mechanisms was more consistently associated with survival >1 day, with one recipient surviving for 31 days. Combining targeted genetic modifications to the lung xenograft with selective innate and adaptive immune suppression enables prolonged initial life-supporting lung function and extends lung xenograft recipient survival, and illustrates residual barriers and candidate treatment strategies that may enable the clinical application of other organ xenografts. 相似文献
7.
Pallawi Torka MD Othman S. Akhtar MD Nishitha M. Reddy MD Bora E. Baysal MD PhD Angela Kader BA CCRP Adrienne Groman MS Jenna Nichols RN MS CCRC Cory Mavis BS MS Joseph D. Tario PhD AnneMarie W. Block PhD Sheila N. J. Sait PhD Paola Ghione MD Suchitra Sundaram MD Eugene R. Przespolewski PharmD BCOP Alice Mohr FNP-C MSN Ian Lund PA-C Jessica Kostrewa NP Kenneth McWhite PA Joseph DeMarco PA Michael Johnson DNP BSN NP RN Andrea Darrall NP Rosh-Neke Thomas-Talley FNP-BC Paul K. Wallace PhD Vishala Neppalli MD Alan Hutson PhD Francisco J. Hernandez-Ilizaliturri MD 《Cancer》2022,128(8):1595-1604
8.
Elisa Moya-Sáez Rafael Navarro-González Santiago Cepeda Ángel Pérez-Núñez Rodrigo de Luis-García Santiago Aja-Fernández Carlos Alberola-López 《NMR in biomedicine》2022,35(9):e4754
Glioblastoma is an aggressive and fast-growing brain tumor with poor prognosis. Predicting the expected survival of patients with glioblastoma is a key task for efficient treatment and surgery planning. Survival predictions could be enhanced by means of a radiomic system. However, these systems demand high numbers of multicontrast images, the acquisitions of which are time consuming, giving rise to patient discomfort and low healthcare system efficiency. Synthetic MRI could favor deployment of radiomic systems in the clinic by allowing practitioners not only to reduce acquisition time, but also to retrospectively complete databases or to replace artifacted images. In this work we analyze the replacement of an actually acquired MR weighted image by a synthesized version to predict survival of glioblastoma patients with a radiomic system. Each synthesized version was realistically generated from two acquired images with a deep learning synthetic MRI approach based on a convolutional neural network. Specifically, two weighted images were considered for the replacement one at a time, a T2w and a FLAIR, which were synthesized from the pairs T1w and FLAIR, and T1w and T2w, respectively. Furthermore, a radiomic system for survival prediction, which can classify patients into two groups (survival >480 days and 480 days), was built. Results show that the radiomic system fed with the synthesized image achieves similar performance compared with using the acquired one, and better performance than a model that does not include this image. Hence, our results confirm that synthetic MRI does add to glioblastoma survival prediction within a radiomics-based approach. 相似文献
9.
Introduction and objectivesOptimal treatment of hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) remains controversial.Materials and methodsA total of 627 HCC patients with PVTT after initial treatment with one of the following at Affiliated Tumor Hospital of Guangxi Medical University: liver resection (LR, n = 225), transarterial chemoembolization (TACE, n = 298) or sorafenib (n = 104) were recruited and randomly divided into the training cohort (n = 314) and internal validation cohort (n = 313). Survival analysis were repeated after stratifying patients by Cheng PVTT type.ResultsResection led to significantly higher OS than the other two treatments among patients with type I or II PVTT. TACE worked significantly better than the other two treatments for patients with type III. All three treatments were associated with similar OS among patients with type IV. These findings were supported by the internal validation cohort.ConclusionsOur results suggest that the optimal treatment for HCC involving PVTT depends on the type of PVTT. LR may be more appropriate for type I or II PVTT; TACE, for type III Sorafenib may be more appropriate than invasive treatments for patients with type IV PVTT. 相似文献
10.
Survival Rate and Prognostic Factors for Colorectal Cancer in Sabah,Borneo, Malaysia: A Retrospective Cohort of a Population-Based Study 下载免费PDF全文
Puteri Nureylia AmirRichard AvoiSiti Norbayah YusofSyed Sharizman Syed Abdul RahimFredie RobinsonNelbon GiloiMuhammad Aklil Abd RahimNaing Oo ThaMohd Yusof IbrahimMohammad Saffree JeffreeFirdaus Hayati 《Asian Pacific journal of cancer prevention》2022,23(6):1885-1891
Background: Colorectal cancer is a major public health problem with significant number of cases and death in the population. This study aimed to determine the 5-year overall survival rate and the prognostic factors for colorectal cancer patients in Sabah. Methods: This was a retrospective cohort study conducted using secondary data from Malaysian National Cancer Registry (MNCR) database. A 5-year overall survival and the median survival time were determined with Kaplan-Meier survival curve. Cox regression analysis was done to determine the prognostic factors on survival. Results: A total of 1,152 patients were included in this study. The majority of the patients had colon cancer and presented at late stage (stage III and IV) as compared to early stage (stage I and II). From the analysis, the 5-year overall survival for colorectal cancer was 23.2% (95% CI: 21.8, 24.6) and the median survival time was 16 months (95% CI: 14.3, 17.7). Higher survivals are seen in males (23.6%, 95% CI: 20.4, 24.7), aged 50-74 years old (24.2%, 95% CI: 22.4, 26.0), Chinese (25.5%, 95% CI: 23.0, 28.0), lived in Keningau (25.6%, 95% CI: 20.8, 30.4), colon as primary tumor site (24.5%, 95% CI: 22.5, 26.4), diagnosed with stage I (55.6%, 95% CI: 48.7, 62.5) and received surgery with chemotherapy or radiotherapy (31.3%, 95% CI: 27.8, 34.8). The significant prognostic factor was the stage at diagnosis. Patients with stage IV colorectal cancer (HR: 11.18; 95% CI: 3.48, 35.93) had eleven times risk of dying as compared to stage I. Conclusion: The survival rate for colorectal cancer patients in Sabah was comparatively lower than other states in Malaysia and in some Asian countries. Those patients who presented at later stage had poorer survival. Health promotion and community-based screening program should be emphasized in addition to encouraging early diagnosis to improve survival. 相似文献